BioMaxima S.A.

Warsaw Stock Exchange BMX.WA

BioMaxima S.A. Current Liabilities for the year ending December 31, 2023: USD 2.65 M

BioMaxima S.A. Current Liabilities is USD 2.65 M for the year ending December 31, 2023, a 5.66% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

BioMaxima S.A. Current Liabilities for the year ending December 31, 2022 was USD 2.51 M, a -41.63% change year over year.
BioMaxima S.A. Current Liabilities for the year ending December 31, 2021 was USD 4.29 M, a 26.04% change year over year.
BioMaxima S.A. Current Liabilities for the year ending December 31, 2020 was USD 3.40 M, a 2.64% change year over year.
BioMaxima S.A. Current Liabilities for the year ending December 31, 2019 was USD 3.32 M, a -35.53% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Warsaw Stock Exchange: BMX.WA

BioMaxima S.A.

CEO	Mr. Lukasz Urban
IPO Date	July 21, 2010
Location	Poland
Headquarters	ul. VetterOw 5
Employees	115
Sector	Consumers Staples
Industries Personal Care Biotechnology Cleaning Supplies Fertilizers Medical Instruments Petrochemicals Pharmaceuticals Plastics

Description

BioMaxima S.A. manufactures and distributes reagents for in vitro diagnostics in Poland. Its primary products include diagnostic reagents and analyzers for clinical chemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; and additives and supplements for media. It supplies its products to approximately 2,000 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 2002 and is based in Lublin, Poland.

Key trends

Past 5 years